Авастин в лечении метастатического колоректального рака

Якушева Татьяна Александровна, Л.М. Когония, Alex Fedotov et al. · Российский биотерапевтический журнал · 2010

The drug armamentarium for treatment of metastatic colorectal cancer has been extended with the introduction of target therapy including Avastin (Bevacizumab), chimeric monoclonal humanized antibody raised against VEGF. Avastin is the first effective anti-angiogenic drug. The combination of chemotherapy (Oxaliplatin, Irinotecan etc.)with Avastin increases the survival of patients with colorectal cancer undergone to I or II line of chemotherapy. This was documented by the results of controlled randomized clinical trials.

Cited by 1 works.

Authors